Cargando…
Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256414/ https://www.ncbi.nlm.nih.gov/pubmed/30519237 http://dx.doi.org/10.3389/fimmu.2018.02606 |
| _version_ | 1783374142676926464 |
|---|---|
| author | King, Lisa A. Lameris, Roeland de Gruijl, Tanja D. van der Vliet, Hans J. |
| author_facet | King, Lisa A. Lameris, Roeland de Gruijl, Tanja D. van der Vliet, Hans J. |
| author_sort | King, Lisa A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6256414 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-62564142018-12-05 Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond King, Lisa A. Lameris, Roeland de Gruijl, Tanja D. van der Vliet, Hans J. Front Immunol Immunology Frontiers Media S.A. 2018-11-20 /pmc/articles/PMC6256414/ /pubmed/30519237 http://dx.doi.org/10.3389/fimmu.2018.02606 Text en Copyright © 2018 King, Lameris, de Gruijl and van der Vliet. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Immunology King, Lisa A. Lameris, Roeland de Gruijl, Tanja D. van der Vliet, Hans J. Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond |
| title | Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond |
| title_full | Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond |
| title_fullStr | Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond |
| title_full_unstemmed | Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond |
| title_short | Corrigendum: CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond |
| title_sort | corrigendum: cd1d-invariant natural killer t cell-based cancer immunotherapy: α-galactosylceramide and beyond |
| topic | Immunology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6256414/ https://www.ncbi.nlm.nih.gov/pubmed/30519237 http://dx.doi.org/10.3389/fimmu.2018.02606 |
| work_keys_str_mv | AT kinglisaa corrigendumcd1dinvariantnaturalkillertcellbasedcancerimmunotherapyagalactosylceramideandbeyond AT lamerisroeland corrigendumcd1dinvariantnaturalkillertcellbasedcancerimmunotherapyagalactosylceramideandbeyond AT degruijltanjad corrigendumcd1dinvariantnaturalkillertcellbasedcancerimmunotherapyagalactosylceramideandbeyond AT vandervliethansj corrigendumcd1dinvariantnaturalkillertcellbasedcancerimmunotherapyagalactosylceramideandbeyond |